Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 8
2003 2
2004 5
2005 4
2006 1
2007 4
2008 2
2009 1
2010 6
2011 4
2012 6
2013 4
2014 10
2015 8
2016 9
2017 7
2018 3
2019 2
2020 13
2021 22
2022 10
2023 12
2024 12
2025 7
2026 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean hideaki hiraishi (1 results)?
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Schoser B, Roberts M, Byrne BJ, Sitaraman S, Jiang H, Laforêt P, Toscano A, Castelli J, Díaz-Manera J, Goldman M, van der Ploeg AT, Bratkovic D, Kuchipudi S, Mozaffar T, Kishnani PS; PROPEL Study Group. Schoser B, et al. Lancet Neurol. 2021 Dec;20(12):1027-1037. doi: 10.1016/S1474-4422(21)00331-8. Lancet Neurol. 2021. PMID: 34800400 Clinical Trial.
104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).
Schoser B, Kishnani PS, Bratkovic D, Byrne BJ, Claeys KG, Díaz-Manera J, Laforêt P, Roberts M, Toscano A, van der Ploeg AT, Castelli J, Goldman M, Holdbrook F, Sitaraman Das S, Wasfi Y, Mozaffar T; ATB200-07 Study Group. Schoser B, et al. J Neurol. 2024 May;271(5):2810-2823. doi: 10.1007/s00415-024-12236-0. Epub 2024 Feb 28. J Neurol. 2024. PMID: 38418563 Free PMC article. Clinical Trial.
Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.
Kishnani PS, Byrne BJ, Claeys KG, Díaz-Manera J, Dimachkie MM, Kushlaf H, Mozaffar T, Roberts M, Schoser B, Hummel N, Kopiec A, Holdbrook F, Shohet S, Toscano A; PROPEL Study Group. Kishnani PS, et al. J Patient Rep Outcomes. 2024 Nov 13;8(1):132. doi: 10.1186/s41687-024-00805-w. J Patient Rep Outcomes. 2024. PMID: 39535661 Free PMC article. Clinical Trial.
Genetic Analysis of SCN11A, SCN10A, and SCN9A in Familial Episodic Pain Syndrome (FEPS) in Japan and Proposal of Clinical Diagnostic Criteria.
Noguchi A, Tezuka T, Okuda H, Kobayashi H, Harada KH, Yoshida T, Akioka S, Wada K, Takeya A, Kabata-Murasawa R, Kondo D, Ishikawa K, Asano T, Fujiwara M, Hishikawa N, Mizukami T, Hitomi T, Youssefian S, Nagai Y, Tanaka M, Eto K, Shiraishi H, Amaya F, Koizumi A, Takahashi T. Noguchi A, et al. Among authors: shiraishi h. Int J Mol Sci. 2024 Jun 21;25(13):6832. doi: 10.3390/ijms25136832. Int J Mol Sci. 2024. PMID: 38999942 Free PMC article.
A phase III double-blind, placebo-controlled, randomized withdrawal trial of 5‑aminolevulinic acid hydrochloride with sodium ferrous citrate for efficacy and safety in patients diagnosed as Leigh syndrome.
Ohtake A, Abe Y, Murayama K, Shiraishi H, Osaka H, Kumada S, Ito T, Kondo H, Hamada Y, Suzuki-Ajihara S, Arao M, Ueda Y, Nagai K, Ichimoto K, Matsunaga A, Kashii H, Nakajima Y, Nakagawa H, Kurose S, Fukuda K, Takahashi K, Yamauchi M, Nakajima M. Ohtake A, et al. Among authors: shiraishi h. PLoS One. 2026 Jul 17;21(7):e0332283. doi: 10.1371/journal.pone.0332283. eCollection 2026. PLoS One. 2026. PMID: 42467686 Free PMC article. Clinical Trial.
Efficacy and Safety of 5-Aminolevulinic Acid Hydrochloride Combined with Sodium Ferrous Citrate in Pediatric Patients with Leigh Syndrome and Central Nervous System Disorders: An Initial Exploratory Trial with a Double-Blind Placebo-Controlled Period, Followed by an Open-Label Period and a Subsequent Long-Term Administration Study.
Abe Y, Hamasaki T, Natsume J, Mogami Y, Murayama K, Shiraishi H, Abe Y, Kumada S, Tanaka R, Ihara K, Sakakibara T, Okazaki Y, Nakagawa H, Takahashi K, Yamauchi M, Nakajima M, Ohtake A. Abe Y, et al. Among authors: shiraishi h. Life (Basel). 2025 Jul 23;15(8):1168. doi: 10.3390/life15081168. Life (Basel). 2025. PMID: 40868816 Free PMC article.
146 results